Investigation of leptin receptor rs1137101 G > A polymorphism with cancer risk: evidence from 35,936 subjects.

Investigation of leptin receptor rs1137101 G>A polymorphism with cancer risk: evidence from 35,936 subjects. Biosci Rep. 2019 Jun 13;: Authors: Rong G, Tang W, Wang Y, Qiu H, Chen S Abstract Leptin receptor (LEPR) signaling may involve in promoting angiogenesis and proliferation, inhibiting apoptosis and plays a vital role in the progression of carcinogenesis. A number of studies have focused on the association of LEPR rs1137101 variants with susceptibility of cancer, however, the observed results were controversial. We searched literature on the relationship of LEPR rs1137101 G>A polymorphism with cancer risk by using PubMed and Embase databases, covering all publications up to October 14, 2018. In total, 44 case-control studies with 35,936 subjects were included. After combining all eligible studies, we identified null relationship between LEPR gene rs1137101 G>A polymorphism and overall cancer risk (A vs. G: OR = 0.97, 95% CI = 0.89-1.06, P  = 0.547; AA vs. GG: OR = 0.93, 95% CI = 0.78-1.13, P  = 0.476; AA/GA vs. GG: OR = 0.99, 95% CI = 0.91-1.09, P  = 0.890 and AA vs. GA/GG: OR =0.92, 95%CI = 0.82-1.04, P  = 0.198). However, in a subgroup analysis, there was an increased susceptibility of oral and oropharyngeal cancer in AA vs. GA/GG genetic model (OR, 1.83; 95% CI, 1.01-3.33; P =0.048). Considering the limited participants were included, the findings might be underpowered. S...
Source: Bioscience Reports - Category: Biomedical Science Authors: Tags: Biosci Rep Source Type: research